Observational studyRespiratory research2019
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
Observational study in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2022Guideline
- Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis.Molecular biology reports · 2020Trial
- Plasma apolipoprotein E protein attenuates pulmonary fibrosis through LRP1 and PLAU dual receptor-mediated TGF-β/Smad inhibition.Journal of advanced research · 2026Article
- Immunological mechanisms and therapeutic approaches in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.Respiratory research · 2026Article
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- Review
- Large scale plasma proteomic profiles improve prediction of idiopathic pulmonary fibrosis in general population.Respiratory research · 2025Article
- Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis.Respiratory research · 2025Observational
- Protein biomarkers of interstitial lung abnormalities in relatives of patients with pulmonary fibrosis.The European respiratory journal · 2025Article
- High matrix stiffness promotes senescence of type II alveolar epithelial cells by lysosomal degradation of lamin A/C in pulmonary fibrosis.Respiratory research · 2025Article
- Review
- The Intersection between Immune System and Idiopathic Pulmonary Fibrosis-A Concise Review.Fibrosis (Hong Kong, China) · 2025Article
- Macrophage Immunometabolism in Pulmonary Homeostasis and Chronic Lung Diseases.International journal of biological sciences · 2025Review
- Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis.ERJ open research · 2024Article
- Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.BMC pulmonary medicine · 2024Article
- Identification of a fibronectin-binding protein signature associated with idiopathic pulmonary fibrosis.Cells & development · 2024Article
- Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2024Article
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.Chinese medical journal pulmonary and critical care medicine · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which diagnosis and management remain challenging. Defining the circulating proteome in IPF may identify targets for biomarker development. We sought to quantify the circulating proteome in IPF, determine differential protein expression between subjects with IPF and controls, and examine relationships between protein expression and markers of disease severity.
methodsThis study involved 300 patients with IPF from the IPF-PRO Registry and 100 participants without known lung disease. Plasma collected at enrolment was analysed using aptamer-based proteomics (1305 proteins). Linear regression was used to determine differential protein expression between participants with IPF and controls and associations between protein expression and disease severity measures (percent predicted values for forced vital capacity [FVC] and diffusion capacity of the lung for carbon monoxide [DLco]; composite physiologic index [CPI]). Multivariable models were fit to select proteins that best distinguished IPF from controls.
resultsFive hundred fifty one proteins had significantly different levels between IPF and controls, of which 47 showed a |log
conclusionsPatients with IPF have a distinct circulating proteome and can be distinguished using a nine-protein profile. Several proteins strongly associate with disease severity. The proteins identified may represent biomarker candidates and implicate pathways for further investigation.
trial registrationClinicalTrials.gov (NCT01915511).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.